January 9, 2014 – Triphase was spun out of the Ontario Institute for Cancer Research to develop and advance late pre-clinical, Phase I or early Phase II potential products.
Read More from Triphase Signs Collaboration and Option Agreement with Celgene Corporation
November 13, 2012 – Cellax™, invented by OICR researchers, is a drug-polymer conjugate based on the proprietary NanoCMC™ technology.
Read More from OICR and MaRS Innovation announce funding for the development of Cellax™
June 7, 2012 – OICR will provide $1.5 million for the development of FV-162, a highly potent, orally-delivered small molecule proteasome inhibitor for multiple myeloma and some forms of Non-Hodgkin’s lymphoma.
Read More from Fluorinov Pharma Inc. develops drug for the treatment of blood cancers
January 30, 2012 – Investors in the Series A round included CTI Life Sciences Fund L.P., Qiagen N.V. and Ontario Capital Growth Corporation through its Emerging Technologies Fund.
May 3, 0206 – Triphase is expanding its current collaboration with Celgene in the development of marizomib for the potential treatment of malignant gliomas.
Read More from Triphase Accelerator Corporation Announces Expansion of Collaboration with Celgene